Plus the adult SR-aGvHD trial that will more likely get the FDA green light as the potency assay has been sorted out. Let’s not forget that the market for adult SR-aGvHD is 5 times bigger than the paediatric one.
Plus the adult SR-aGvHD trial that will more likely get the FDA...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
0.000(0.00%) |
Mkt cap ! $1.210B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.09 | $1.05 | $2.827M | 2.656M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 19031 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 58013 | 10 |
View Market Depth
| Last trade - 13.38pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.08 |
Change
0.000 ( 0.53 %) |
||||
| Open | High | Low | Volume | ||
| $1.07 | $1.09 | $1.05 | 551871 | ||
| Last updated 13.57pm 17/06/2024 ? | |||||
| MSB (ASX) Chart |
